260 results  1 of 14 

1 제주 지역의 30년간 염증성 장질환의 동향
Jin Woo Kim, Hyun Joo Song, Sun-Jin Boo, Heung Up Kim, Ki Soo Kang, Soo-Young Na
Korean J Gastroenterol.2023;81(6):243-252.   Published online 2023 June 25     DOI: http://dx.doi.org/10.4166/kjg.2023.006
      
2 Risk Factors for the Occurrence and Severity of Vertebral Fractures in Inflammatory Bowel Disease Patients: A Nationwide Population-Based Cohort Study
Arum Choi, Sung Hoon Jung, Sukil Kim, Jun-Seok Lee
J Korean Med Sci.2023;38(28):e210.  Published online 2023 June 8     DOI: http://dx.doi.org/10.3346/jkms.2023.38.e210
      
3 Inflammatory bowel disease–associated intestinal fibrosis
Ji Min Park, Jeongseok Kim, Yoo Jin Lee, Sung Uk Bae, Hye Won Lee
J Pathol Transl Med.2023;57(1):60-66.   Published online 2023 January 10     DOI: http://dx.doi.org/10.4132/jptm.2022.11.02
      
4 Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Zerong Cai, Xiaosheng He, Jianfeng Gong, Peng Du, Wenjian Meng, Wei Zhou, Jinbo Jiang, Bin Wu, Weitang Yuan, Qi Xue, Lianwen Yuan, Jinhai Wang, Jiandong Tai, Jie Liang, Weiming Zhu, Ping Lan, Xiaojian Wu
Intest Res.2023;21(2):235-243.   Published online 2022 December 2     DOI: http://dx.doi.org/10.5217/ir.2022.00012
      
5 Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
Intest Res.2023;21(2):252-265.   Published online 2022 December 2     DOI: http://dx.doi.org/10.5217/ir.2022.00092
      
6 Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
Intest Res.2023;21(3):392-405.   Published online 2022 December 2     DOI: http://dx.doi.org/10.5217/ir.2022.00094
      
7 Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease
Soo-Young Na, Won Moon
Clin Endosc.2022;55(6):726-735.   Published online 2022 November 18     DOI: http://dx.doi.org/10.5946/ce.2022.132
      
8 Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice
Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai
Intest Res.2023;21(1):100-109.   Published online 2022 November 14     DOI: http://dx.doi.org/10.5217/ir.2021.00110
      
9 Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD
Arshdeep Singh, Yogesh Kumar Gupta, Ashvin Singh Dhaliwal, Bhavjeet Kaur Kahlon, Vasu Bansal, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Ramandeep Kaur, Namita Bansal, Vandana Midha, Ajit Sood
Intest Res.2023;21(3):375-384.   Published online 2022 October 18     DOI: http://dx.doi.org/10.5217/ir.2022.00037
      
10 Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
Sujin Choi, Eun Sil Kim, Yiyoung Kwon, Mi Jin Kim, Yon Ho Choe, Byung-Ho Choe, Ben Kang
J Korean Med Sci.2022;37(37):e282.  Published online 2022 September 14     DOI: http://dx.doi.org/10.3346/jkms.2022.37.e282
      
11 Clostridioides Infection in Patients with Inflammatory Bowel Disease
Mi Rae Lee, Eun Soo Kim
Korean J Gastroenterol.2022;80(2):66-71.   Published online 2022 August 25     DOI: http://dx.doi.org/10.4166/kjg.2022.097
      
12 Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?
Aikaterini Mantaka, Nikolaos Galanakis, Dimitrios Tsetis, Ioannis E. Koutroubakis
Intest Res.2022;20(4):495-505.   Published online 2022 August 8     DOI: http://dx.doi.org/10.5217/ir.2022.00017
      
13 Clinical spectrum of elderly-onset inflammatory bowel disease in India
Yogesh Kumar Gupta, Arshdeep Singh, Vikram Narang, Vandana Midha, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Namita Bansal, Madeline Vithya Barnaba Durairaj, Amit Kumar Dutta, Ajit Sood
Intest Res.2023;21(2):216-225.   Published online 2022 August 8     DOI: http://dx.doi.org/10.5217/ir.2021.00177
      
14 Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim
Intest Res.2023;21(2):244-251.   Published online 2022 August 8     DOI: http://dx.doi.org/10.5217/ir.2022.00057
      
15 Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
Intest Res.2023;21(1):61-87.   Published online 2022 May 31     DOI: http://dx.doi.org/10.5217/ir.2022.00007
      
16 One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Yuichi Matsuno, Takehiro Torisu, Junji Umeno, Hiroki Shibata, Atsushi Hirano, Yuta Fuyuno, Yasuharu Okamoto, Shin Fujioka, Keisuke Kawasaki, Tomohiko Moriyama, Tomohiro Nagasue, Keizo Zeze, Yoichiro Hirakawa, Shinichiro Kawatoko, Yutaka Koga, Yoshinao Oda, Motohiro Esaki, Takanari Kitazono
Intest Res.2022;20(2):260-268.   Published online 2022 April 29     DOI: http://dx.doi.org/10.5217/ir.2021.00124
      
17 Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
Joo Kyung Kim, Jae Hee Cheon
J Yeungnam Med Sci.2022;40(1):37-48.   Published online 2022 April 18     DOI: http://dx.doi.org/10.12701/jyms.2022.00031
      
18 The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
Gi Hyeon Seo, Sung Hoon Jung
J Korean Med Sci.2022;37(16):e123.  Published online 2022 April 12     DOI: http://dx.doi.org/10.3346/jkms.2022.37.e123
      
19 Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Intest Res.2022;20(4):452-463.   Published online 2022 March 11     DOI: http://dx.doi.org/10.5217/ir.2021.00125
      
20 Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe
Intest Res.2023;21(1):110-125.   Published online 2022 March 11     DOI: http://dx.doi.org/10.5217/ir.2021.00143
      

 1 of 14